under one amp again you know your guitar player problem which you carry the machine time with genentech interrogator. with their country stereotypical you are talking t.v. got a new gen event of which there is a child. and quarter 1000000 shares of them and they can only know. one another and i'm not going. to talk. to. it's ok if he would lie if i don't see a mammoth that will have been old and that unless you need more appalled them we do need mel monet in a sunny paste my vocal that i think i need to visit the addams family the little scene is the month when it meta news leaked into or as i can i was the one you'll see when i'm up i mean. there would have been a concern with them is it was him in malibu sica. of ocean typical a bit of an a lost if his bosses feel daughter opposite there is a method to the teacher that is good. that the vendor could dishes out that at best you can be. visual or does this often is a particle to fully measure a command in quantity if it is good. good good bad. i feel over 12 appeared on. a few. i. think. when you go. to the bank i'm. covered under seal.

in that conference call with therapeutics companies, 2 of those companies also from the bay area, genentech and gilead.. >>> meanwhile the san jose mayor called for the city to allocate more than $17 million in funding to house people who are potential carriers of the coronavirus. >> we have a unique moment to eliminate red tape, to be able to move quickly and nimbly, and to accelerate our efforts. >>> meantime, with many people struggling to pay their bills, 2 san jose city leaders are proposing a rent freeze. john ramos has more on the push. >> reporter: governor newsom imposed the eviction ban so people wouldn't get thrown out of their apartments, but they still owed their landlords back rent. now 2 san jose city council members are taking the next step and saying they shouldn't have to pay anything. council members carrasco and perales says the halt on evictions will do nothing in the long run to keep laid off workers in their homes. >> it only delays the inevitable. 3 or 4 months from now, they'll only have accumulated a massive rent debt. eviction will become almost inevitable. >> rep

i can speak for genentech that we are doing everything we can to ensure we have the capacity to produce medicines that are needed to fight the pandemic, but of course also medicines needed to treat patients with a whole variety of diseases that continue to get sick that do not have covid-19. so this is top of mind and a critical need. i am encouraged that we are up to the challenge. jeanne: pharmaceutical supply is largely dependent on ingredients that come from china, from india. are some of the therapies and vaccines we are looking at now also going to be reliant on those countries? are you convinced that if they are we will be able to get the supplies we need? dr. garraway: as you point out, components for both vaccines and therapeutics typically are generated at sites around the world. so supplying any given country, whether the united states or any other, for a pharmaceutical company is supply. a issue of global supply. certainly, this has been a critically important issue. we have engaged in conversations with our government and other key officials around the need to maintain the

>> president trump says he spoke with several pharmaceutical companies including bay area-based genentechnd gilead. he added ten different therapeutic trials are looking incredibly successful and another 15 treatments are presi that of the world health organization, which says research to develop vaccines and treatments has rapidly accelerated. >>> just in, could major league baseball be back in action by next month, as in may? according to the associated press, the league office is working with federal health officials on a new plan that will put the giants, a's and all 30 teams back on the field. here's the catch. all teams would play strictly in arizona for the first part of the season. you can see the giants are familiar with playing in arizona when they played the diamondbacks. now, all teams would be there in phoenix. the proposal is all teams would play in the phoenix area with no fans. they would test players before each game. now, this is similar to what dwayne kuiper and mike crewco told us just last week. >> you know, maybe they play a partial season in one spot like arizona, a

gilead and not just researching and advancing the trial, but manufacturing here in california and genentechnd that is one of california's great resources and so we hope we are in the front of that curve, as well and as we come out and the treatment of the vaccine side then the economy will start to appear at the kind of scale where the physical distancing becomes less and less significant and ultimately will get to the point of some semblance of normalcy. >> yeah. and i'll wrap it up with this, obviously, because you have in your state facebook and google and the irony is that before all of this came about there were a lot of fights about privacy and sort of, you know, personal data that's been going on for years now we're talking about literally contract tracing and following people around with mobile and internet-enabled thermometers and this is probably more of a congressional argument, but listen, they're probable coming to you too because they're in your state and what are you hearing about privacy concerns and how do you balance this all out >> if i was talking to you last year and th

biotech company genentech announced that they had gotten approval to move on with a drug that treatsrug used to tre arthritis. people who had taken a drug called remdesivir had improved. no one is sure weather remdesivir which was designed for ebola will work for covid-19. beyond drugs, the fda has put out a call for people to donate blood plasma if they've already recovered from coronavirus. their antibodies could help people who are currently suffering. studies are underway in new york and at universities around the country. the ultimate weapon, a vaccine, is moving along at research centers around the world including at the university of oxford in england. they announced they have teamed up with an italian manufacturer to make a vaccine, all with an eye towards putting an end to the pandemic. >> now getting back to remdesivir, the drug that's making headlines this morning, it may turn out to be great, it may turn out to be very useful for covid patients, but it could turn out to be useless. jim and poppy? >> elizabeth, to know that critical question, what else needs to be discover

biotech company genentech announced thursday that the fda had given approval move on with the next stage in trls fo its drug called actemra which is already sed to treat arthritis and other ailments, a similar drug called kevza from manufacturer jenner on this also being studied to treat covid-19 d in a video leaked the health news website stat doctorfrom the university of chicago discussed how their patients anti-viral drucalled remdesivir year were recovering quickly. but it was literally just talk not published research so no one knows for sure not yet anyways whether rammed esta beer which was designed butdidn't work for ebola will work for covid-19. >>and be on drugs e fd has put out a call fopeople to donate blood plasma if they've already revered from coronavirus. >>they're antibodies could help people who are currently s in new york and at universities around the countrythe ultimate weapon research centers around the wold, including at t university of oxford in england. ey announced that they teamed up with an italian manufacturer to make a ccine. all with an eye towards putting

levi garrway, in the chief medical officer of biotech company genentech and roche that are working on treatments for covid-19. good afternoon, dr. garraway. do you hear me? dr. garraway: yes, i do. ms. meserve: there are clinical trials under way for drugs for covid-19. can you give us an update? where are you in that process? dr. garraway: we have a clinical trial underway for medication that was originally developed for, for example, rheumatoid arthritis. way,eason for this, by the is for patients with covid-19 who develop problems, for example, the pneumonia that can cause respiratory failure and the need for intubation and even death, that it is believed part of the reason why that pneumonia happens, at least, it is not continued viral replication, but the immune response or the inflammatory response of the patient to the virus that becomes excessive. so the recognition of that led , initially, several investigators tested the idea that actemra, which was designed to inhibit that type of inflammation, the thought was maybe that would help patients with covid-19 pneumonia. and so t

i can speak for genentech that we are doing everything we can to ensure we have the capacity to produceedicines that are needed to fight the pandemic, but also medicines needed to wholepatients with a variety of diseases that continue to get sick that do not have covid-19. this is top of mind and a critical need. i am encouraged that we are up to the challenge. ms. meserve: i'm a suitable supply is largely dependent on ingredients that come from china, from india. our some of the therapies and vaccines we are looking at now also going to be reliant on those countries? are you convinced that if they are we will be able to get the supplies we need? --dr.rris: dr. garraway: garraway: as you point out, vaccines andr both treatments are produce around the world. it is an issue of global supply. certainly, this has been a critically important issue. we have engaged in conversations with our government and other to officials around the need maintain the global supply chain in order to help patients not only in the u.s. but everywhere. it is a very important issue that we are paying close atten

spoke with leaders of the american pharmaceutical companies and just to give you their names, amgen, genentechgilead, regeneron, four of the greatest in the world for doing exactly what they're doing. and currently 10 different therapeutic agents are in active trials an some are looking incredibly successful we have to go through a process. it will be a fairly quick process, i tell you based on what the fda told me. 15 are in plans for clinical trials. they're advancing rapidly. a second company announced that the fda authorized it is vaccine candidate to begin clinical trials. johnson & johnson is already there. i believe they're the one that's first and now we have a second company that just announced and we were just, was just approved. so we have two companies at that level, for the vaccine itself. we have you no performed 100, well, if you think of this, 1.79 million tests. that is one million, 790,000 tests nationwide. i think we're going to put up a screen here someplace that they're on cue, just on cue. and here it is. this is the process starting on 5 march and ending right there, rig

leaders of the american pharmaceutical companies and just to give you their names, amgen, gilead, genentech, these are some of the greatest in the world for cog that what they're doing. currently ten therapeutic agents are in active trials and some are looking successful. but we have to go through a process. it's going to be a fairly quick process based on what the fda told me. another 15 are in plans for clinical trials. so they're advancing rapidly. today, a second company announced that the fda has authorized its vaccine candidate to begin clinical trials. so johnson & johnson is already there. now we have a second company that just announced and we were just -- it was just approved. so we have two companies at that level for the vaccine. we have now performed 100 -- well, if you think of this, 1.79 million tests. that's 1,790,000 tests nationwide. and i think we're going to put up a screen here some place. they're just on cue. here it is. this is the process starting on 5 march, and ending right there, right about now. that's about it. >> yesterday. >> and it's going up at a rapid rate.

spoke with , leaders of the american pharmaceutical companies and just to give you their names, genentech, giliad, regenron, these are four of the greatest in the world for doing exactly what they're doing. currently 10 different therapeutic agents are in active trials and some are looking incredibly successful. but we have to go through a process and it's going to be a fairly quick process, i will tell you, based on what the fda told me. and another 15 are in plans for clinical trials. they're advancing rapidly. today, a second company announced that the fda has authorized its vaccine candidate to begin clinical trials. you have johnson & johnson is already there. i believe they're the one that's first. now we have a second company that just announced and it was just approved. so we have two companies at that level for the vaccine. we've now performed 100 -- well, if you think of this, 1.79 million tests. that's 1,790,000 tests nationwide. i think we're going to put up a screen here someplace. they are on cue. and here it is. this is the process. starting on 5 march. and ending right the